Research Analysts’ Recent Ratings Changes for Glaukos (GKOS)

A number of research firms have changed their ratings and price targets for Glaukos (NYSE: GKOS):

• 2/21/2026 – Glaukos was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/18/2026 – Glaukos had its price target raised by Needham & Company LLC from $125.00 to $127.00. They now have a “buy” rating on the stock.
• 2/18/2026 – Glaukos had its price target raised by Wells Fargo & Company from $122.00 to $135.00. They now have an “overweight” rating on the stock.
• 2/18/2026 – Glaukos had its “buy” rating reaffirmed by BTIG Research. They now have a $131.00 price target on the stock.
• 2/7/2026 – Glaukos was upgraded by Wall Street Zen from “hold” to “buy”.
• 1/30/2026 – Glaukos was upgraded by William Blair to “strong-buy”.
• 1/28/2026 – Glaukos had its price target raised by BTIG Research from $123.00 to $131.00. They now have a “buy” rating on the stock.
• 1/22/2026 – Glaukos had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/22/2026 – Glaukos had its price target raised by Stifel Nicolaus from $115.00 to $160.00. They now have a “buy” rating on the stock.
• 1/14/2026 – Glaukos had its “overweight” rating reaffirmed by Piper Sandler. They now have a $165.00 price target on the stock.
• 1/14/2026 – Glaukos had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $125.00 price target on the stock.
• 1/9/2026 – Glaukos had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $138.00 price target on the stock.

Insider Buying and Selling at Glaukos

In other news, Director Marc Stapley sold 15,000 shares of the firm’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $127.71, for a total value of $1,915,650.00. Following the transaction, the director owned 37,449 shares of the company’s stock, valued at $4,782,611.79. This trade represents a 28.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gilbert H. Kliman sold 5,000 shares of Glaukos stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total value of $536,350.00. Following the transaction, the director directly owned 34,905 shares in the company, valued at approximately $3,744,259.35. The trade was a 12.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 325,000 shares of company stock worth $37,739,259. 5.80% of the stock is owned by corporate insiders.

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.